Enterprise strategy of Jiangsu Wanbang Biochemical Pharmaceutical Co., Ltd.

Wanbang Medicine follows the strategic principle of "one center and two expansions", focuses on hypoglycemic drugs, expands two major fields of lowering blood pressure and lipid, and gradually cultivates the core competitiveness of Wanbang Medicine by building an education team for diabetic patients covering all levels of consumption in the country. Relying on this core competitiveness and other factors, we will strengthen brand building and consolidate the absolute monopoly position of animal insulin products in the domestic market by maintaining absolute advantages in production technology, cost and quality. To optimize the production process of recombinant human insulin, and explore the domestic preparation market on this basis. At the same time, actively follow the global development direction of oral hypoglycemic agents, form a series combination of Wanbang Pharmaceutical hypoglycemic agents, and rapidly increase the domestic market share of hypoglycemic agents. Selectively develop lipid-lowering and antihypertensive drugs, take advantage of the company's comprehensive advantages and adopt follow-up strategies to occupy part of the lipid-lowering and antihypertensive drug market. Strive to initially build Wanbang into an influential "China Diabetes Medicine Base" within five years, and establish a professional brand image in the field of diabetes treatment in China and the international insulin industry.